.

Make Better Decisions

  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Merck
Boehringer Ingelheim
Chinese Patent Office
US Army
Colorcon
Moodys
Dow
US Department of Justice
Julphar
Mallinckrodt

Generated: December 15, 2017

DrugPatentWatch Database Preview

Details for Patent: 8,192,756

« Back to Dashboard

Which drugs does patent 8,192,756 protect, and when does it expire?


Patent 8,192,756 protects GRALISE and is included in one NDA. There has been one Paragraph IV challenge on Gralise.

This patent has twenty-three patent family members in nine countries.

Summary for Patent: 8,192,756

Title:Gastric retained gabapentin dosage form
Abstract: A method of treatment for epilepsy and other disease states is described, which comprises the delivery of gabapentin in a gastric retained dosage form.
Inventor(s): Berner; Bret (Half Moon Bay, CA), Hou; Sui Yuen Eddie (Foster City, CA), Gusler; Gloria M (Cupertino, CA)
Assignee: Depomed, Inc. (Menlo Park, CA)
Application Number:13/111,575
Patent Claim Types:
see list of patent claims
Compound; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Depomed IncGRALISEgabapentinTABLET;ORAL022544-001Jan 28, 2011BXRXYesYes► Subscribe► SubscribeYTREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA► Subscribe
Depomed IncGRALISEgabapentinTABLET;ORAL022544-002Jan 28, 2011BXRXYesYes► Subscribe► SubscribeYTREATMENT WITH GABAPENTIN, INCLUDING TREATMENT OF NEUROPATHIC PAIN, INCLUDING NEUROPATHIC PAIN ASSOCIATED WITH POSTHERPETIC NEURALGIA► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 8,192,756

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,333,991Gastric retained gabapentin dosage form► Subscribe
8,802,157Methods of treatment using a gastric retained gabapentin dosage form► Subscribe
8,529,955Methods of treatment using a gastric retained gabapentin dosage► Subscribe
7,438,927Methods of treatment using a gastric retained gabapentin dosage► Subscribe
8,333,992Gastric retained gabapentin dosage form► Subscribe
8,580,303Gastric retained gabapentin dosage form► Subscribe
8,409,613Gastric retained gabapentin dosage form► Subscribe
8,252,332Gastric retained gabapentin dosage form► Subscribe
8,119,166Methods of treatment using a gastric retained gabapentin dosage► Subscribe
8,440,232Methods of treatment using a gastric retained gabapentin dosage► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 8,192,756

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia2006332690► Subscribe
Canada2464322► Subscribe
Canada2575555► Subscribe
Canada2635466► Subscribe
China101484153► Subscribe
Denmark1439825► Subscribe
European Patent Office1439825► Subscribe
European Patent Office1773311► Subscribe
European Patent Office1976503► Subscribe
European Patent Office2266539► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

QuintilesIMS
Johnson and Johnson
Chubb
Chinese Patent Office
McKinsey
Baxter
Citi
Medtronic
Boehringer Ingelheim
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot